8 reports

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Eye Disease
  • Therapy
  • Biomay AG

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Eye Disease
  • Therapy
  • Biomay AG

HALMRE-## - DRUG PROFILE POLLINEX QUATTRO GRASS - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Pollinex Quattro Grass Allergy Therapeutics Plc NA GlaxoSmithKline Plc R& D Progress Resea

  • Allergy Drug
  • Eye Disease
  • Ophthalmic Solution
  • Pharmaceutical
  • Product Initiative

The drug candidate binds to and inhibits the mRNA of Orai ##, inhibiting the calcium transport.

  • Antifungal
  • Eye Disease
  • Therapy
  • United States
  • Aldeyra Therapeutics, Inc.

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antifungal
  • Infectious Disease
  • Pharmaceutical
  • Therapy
  • SCYNEXIS, Inc.

Subjects orally took study drug once daily in the evening for one month.

  • Eye Disease
  • Ophthalmology
  • Therapy
  • United States
  • Product Initiative

Subjects orally took study drug once daily in the evening for one month.

  • Eye Disease
  • Ophthalmology
  • Therapy
  • United States
  • Product Initiative

(allergy and autoimmune diagnostics) which was sold to Thermo Fisher Scientific (TMO) in September of 2011.

  • Eye Disease
  • Research And Development
  • United States
  • Company
  • ProQR Therapeutics N.V.